CA3199479A1 - Formulation de poudre seche de muteine de la lipocaline pour le traitement de l'asthme - Google Patents

Formulation de poudre seche de muteine de la lipocaline pour le traitement de l'asthme

Info

Publication number
CA3199479A1
CA3199479A1 CA3199479A CA3199479A CA3199479A1 CA 3199479 A1 CA3199479 A1 CA 3199479A1 CA 3199479 A CA3199479 A CA 3199479A CA 3199479 A CA3199479 A CA 3199479A CA 3199479 A1 CA3199479 A1 CA 3199479A1
Authority
CA
Canada
Prior art keywords
dry powder
fragment
variant
lipocalin mutein
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3199479A
Other languages
English (en)
Inventor
Mary Fitzgerald
David Robert Close
Philip Gardiner
Robert Alexander Palmer
Marja Riikka SAVOLAINEN
Sandra Gracin
Ankur AJMERA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CA3199479A1 publication Critical patent/CA3199479A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Abstract

La présente invention concerne le traitement de l'asthme chez un sujet humain par administration par inhalation orale d'une formulation de poudre sèche comprenant une quantité thérapeutiquement efficace d'une mutéine de la lipocaline anti-chaîne alpha du récepteur de l'IL-4 (IL-4 R?), ou une variante ou un fragment de celle-ci, audit sujet. L'invention concerne également la formulation de poudre sèche comprenant la mutéine de la lipocaline anti-chaîne alpha du récepteur de l'IL-4 (IL -4 R?), ou une variante ou un fragment de celle-ci.
CA3199479A 2020-12-18 2021-12-20 Formulation de poudre seche de muteine de la lipocaline pour le traitement de l'asthme Pending CA3199479A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063127903P 2020-12-18 2020-12-18
US63/127,903 2020-12-18
PCT/EP2021/086730 WO2022129629A1 (fr) 2020-12-18 2021-12-20 Formulation de poudre sèche de mutéine de la lipocaline pour le traitement de l'asthme

Publications (1)

Publication Number Publication Date
CA3199479A1 true CA3199479A1 (fr) 2022-06-23

Family

ID=79686778

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3199479A Pending CA3199479A1 (fr) 2020-12-18 2021-12-20 Formulation de poudre seche de muteine de la lipocaline pour le traitement de l'asthme

Country Status (13)

Country Link
EP (1) EP4262845A1 (fr)
JP (1) JP2023553703A (fr)
KR (1) KR20230121785A (fr)
CN (1) CN116916945A (fr)
AR (1) AR124436A1 (fr)
AU (1) AU2021399151A1 (fr)
CA (1) CA3199479A1 (fr)
CL (1) CL2023001775A1 (fr)
CO (1) CO2023007904A2 (fr)
CR (1) CR20230265A (fr)
IL (1) IL303729A (fr)
TW (1) TW202241490A (fr)
WO (1) WO2022129629A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019255A1 (fr) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteines de la lipocaline lacrymale
CA2659413C (fr) 2006-08-01 2016-06-14 Pieris Ag Muteines de lipocaline lacrymale et procedes permettant d'obtenir lesdites muteines
CN105949301B (zh) 2010-06-08 2020-03-27 皮里斯制药有限公司 结合IL-4受体α的泪脂质运载蛋白突变蛋白
DK3453400T3 (da) 2011-12-13 2021-04-06 Pieris Pharmaceuticals Gmbh Fremgangsmåder til forebyggelse eller behandling af visse forstyrrelser ved inhibering af binding af il-4 og/eller il-13 til deres respektive receptorer
EP3946417A1 (fr) * 2019-03-29 2022-02-09 Pieris Pharmaceuticals GmbH Administration inhalée de mutéines de lipocaline
WO2020200960A1 (fr) 2019-03-29 2020-10-08 Astrazeneca Ab Mutéine de lipocaline pour le traitement de l'asthme

Also Published As

Publication number Publication date
AR124436A1 (es) 2023-03-29
IL303729A (en) 2023-08-01
WO2022129629A1 (fr) 2022-06-23
CR20230265A (es) 2023-09-29
CN116916945A (zh) 2023-10-20
CL2023001775A1 (es) 2024-01-19
EP4262845A1 (fr) 2023-10-25
TW202241490A (zh) 2022-11-01
JP2023553703A (ja) 2023-12-25
AU2021399151A1 (en) 2023-07-27
KR20230121785A (ko) 2023-08-21
CO2023007904A2 (es) 2023-10-30

Similar Documents

Publication Publication Date Title
AU2018286571B2 (en) Liquid inhalation formulation comprising RPL554
US7855177B1 (en) Methods and kits for preventing hypoglycemia
JP2003519175A (ja) インターロイキン−２の肺送達のための方法
KR20100047866A (ko) 약제학적 폴리펩타이드 건조 분말 에어로졸 제형 및 이의 제조 방법
US20140378394A1 (en) Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
AU2023202420A1 (en) Compositions, devices, and methods for the treatment of alcohol use disorder
US20220265549A1 (en) Pharmaceutical composition comprising ensifentrine
US20220193191A1 (en) Lipocalin mutein for treatment of asthma
US20200390691A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
CA3199479A1 (fr) Formulation de poudre seche de muteine de la lipocaline pour le traitement de l'asthme
KR20020097033A (ko) 당뇨병 환자에게서 공복시 당 및 체중 증가를 감소시키는방법
AU2021200396B2 (en) Pharmaceutical composition containing budesonide and formoterol
US20100063251A1 (en) Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases
JPH0242027A (ja) 経粘膜吸収促進剤及びこれを用いた経鼻投与剤
WO2023014906A1 (fr) Compositions et procédés pour le traitement d'une surdose d'opioïdes